PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
Status:
Withdrawn
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study of CX-188 is to characterize the safety,
tolerability, pharmacokinetics (PK), and antitumor activity of CX-188 in adult subjects with
metastatic or advanced unresectable solid tumors that progressed on standard therapy:
PROCLAIM: PRObody Clinical Assessment in Man CX-188 clinical trial 001